Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s
Abstract
Comparative study of antitumor activity of cisplatin and dioxadet in chemoperfusion treatment was carried out on ascitic ovarian cancer model in 172 Vistar female rats. Ovarian cancer was inoculated intraperitoneally at a volume of 0.5 ml per rat with concentration of tumor cells 2×107 / ml. The drugs were administered once in 48 hours after inoculation of ovarian cancer in maximum tolerated doses (MTD). Normothermic intraperitoneal chemoperfusion (IPEC) and hyperthermic intraperitoneal chemoperfusion (HIPEC) were performed with cisplatin or dioxadet at doses that were 5−20 times higher than those for their standard intraperitoneal administration. Antitumor effects of the drugs were estimated in increase of median survival time (MST). In case of IPEC and HIPEC cisplatin increased the MST by 317 % and 183 % (р<0.05) respectively, when dioxadet increased the MST by 244 % and 444 % (р<0.05) respectively compared to the control group of animals that didn’t receive any treatment. HIPEC with dioxadet is the most effective regimen in experimental treatment of advanced ovarian cancer.
About the Authors
V. G. BespalovRussian Federation
О. А. Belyaeva
Russian Federation
G. S. Kireeva
Russian Federation
K. Yu. Senchik
Russian Federation
A. N. Stukov
Russian Federation
A. M. Belyaev
Russian Federation
References
1. Beljaeva O.A., Bespalov V.G., Senchik K.Ju., Kon’kov S.A., Stukov A.N., Murazov Ja.G., Aleksandrov V.A. Chemoperfusion treatment for cancer // Medlajn jekspress. 2011. № 2–3. P. 48–52. [in Russian]
2. Bespalov V.G., Beljaeva O.A., Panchenko A.V., Stukov A.N., Gershanovich M.L., Latipova D.H., Murazov Ja.G., Kon’kov S.A., Kil’maeva N.E., Krylova I.M., Mironjuk T.A. Comparative study of antitumor effect of cytostatic agents using the model of ascitic ovarian cancer // Medlajn jekspress. 2011. № 2–3. P. 48–52. [in Russian]
3. Bespalov V.G., Zhabin A.A., Stukov A.N., Beljaeva O.A., Murazov Ja.G., Semenov A.L., Kon’kov S.A., Krylova I.M. Synergism of antitumor action of dioxadet and cisplatin in model of ascitic ovarian tumor // Sibirskij onkologicheskij zhurnal. 2013. № 1 (55). P. 42–46. [in Russian]
4. Cancer incidence in Russia in 2011 (morbidity and mortality) / Eds. V.I. Chissov, V.V. Starinskiy, G.V. Petrova. М., 2013. 230 p. [in Russian]
5. Stukov A.N., Gershanovich M.L., Blank M.A et al. Antitumor agents. SPb.: NIKA, 2011. 656 p. 6. Chua T.C., Robertson G., Liauw W., Farrell R., Yan T.D., Morris D.L. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results // J. Cancer Res. Clin. Oncol. 2009. Vol. 135. P. 1637–1645.
6. Kwa M., Muggia F. Ovarian cancer: A brief historical overview of intraperitoneal trials // Ann. Surg. Oncol. 2014. Vol. 21 (5). P. 1429–1434. doi: 10.1245.
7. Mulier S., Claes J.P., Dierieck V., Amiel J.O., Pahaut J.P., Marcelis L., Bastin F., Vanderbeeken D., Finet C., Cran S., Velu T. Survival benefit of adding Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence // Curr. Pharm. Des. 2012. Vol.18. P. 3793–3803.
Review
For citations:
Bespalov V.G., Belyaeva О.А., Kireeva G.S., Senchik K.Yu., Stukov A.N., Belyaev A.M. Intraperitoneal CHEMOPERFUSION TREATMENT OF ADVANCED OVARIAN CANCER WITH DIOXADET COMPARED TO CISPLATIN in experimental s. Siberian journal of oncology. 2014;(2):14-18. (In Russ.)